Sprint Bioscience AB

Equities

SPRINT

SE0006343745

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 15:59:28 04/06/2024 BST			5-day change	1st Jan Change
1.26 ^SEK	+0.64%		+3.96%	-27.38%

05-08	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-14	Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Sprint Bioscience Q3 2022 - Seal the deal

October 26, 2022 at 02:34 pm

Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project in late 2022e or H1 2023e. We preliminarily adjust our valuation for the company’s recently announced rights issue and increased cost control measures.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Latest news about Sprint Bioscience AB

Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-14	CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	25/10/23	CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Sprint Bioscience Licenses the Vada Program to Day One Biopharmaceuticals	16/08/23	CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2022	15/02/23	CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	15/02/23	CI
Vivesto Names Sprint Bioscience Boss as New CEO; Shares Down 6%	21/11/22	MT
Sprint Bioscience Reports Novel AMLarget Proteins in Ongoing Collaboration	08/11/22	CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	26/10/22	CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	24/08/22	CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22	CI
Sprint Bioscience Launches NIMA at BIO International	05/05/22	CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	16/02/22	CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	27/10/21	CI
Sprint Bioscience AB Initiates Marketing of an Additional Cancer Drug Program	27/09/21	CI
Sprint Bioscience : Launches New Cancer-Focused Clinical Program	08/09/21	MT
Sprint Bioscience AB Adds New Cancer Drug Program to its Project Portfolio	08/09/21	CI
Sprint Bioscience AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Sprint Bioscience Licenses the Cancer Drug Program Vps34 to Deciphera Pharmaceuticals	03/08/21	CI
Sprint Bioscience AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	12/05/21	CI
Sprint Bioscience AB announced that it has received SEK 20.713701 million in funding	07/04/21	CI
Sprint Bioscience : Appoints New CEO	26/02/21	MT

Chart Sprint Bioscience AB

Duration

Period

More charts

Company Profile

Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâs strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPRINT BIOSCIENCE AB	-27.38%	8.39M
VERTEX PHARMACEUTICALS INCORPORATED	+15.39%	121B
REGENERON PHARMACEUTICALS, INC.	+13.45%	107B
BIONTECH SE	-5.29%	24.82B
ARGENX SE	+1.63%	22.48B
GENMAB A/S	-10.09%	18.32B
WUXI APPTEC CO., LTD.	-42.28%	16.33B
BEIGENE, LTD.	-15.85%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+3.35%	14.08B
SAREPTA THERAPEUTICS, INC.	+24.33%	11.74B

Bio Therapeutic Drugs